DiaMedica Therapeutics, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Note 13 - Related Party Transaction

Note 13 - Related Party Transaction

9 Months Ended

Sep. 30, 2020

13.	Related Party Transaction

During

2020,

we have engaged a consulting firm owned by our Vice President of Regulatory Affairs to perform certain tasks supporting our quality and regulatory activities. The work is performed as required by us and all services are invoiced on an hourly basis with

minimum commitment. Total charges invoiced were approximately

$90,000

and

$137,000

for the

three

and

nine

-months ended

September 30, 2020,

and are recorded as research and development expenses, of which

$11,000

is outstanding and included in accounts payable as of

September 30, 2020.